Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.
OBJECTIVE
To determine the safety and efficacy of intravenous total dose iron (TDI) replacement in patients treated with home renal replacement therapy.


METHODS
Prospective open-label study on end points in the population studied.


METHODS
Institutional outpatient home dialysis program.


METHODS
The study included 20 end-stage renal disease (ESRD) patients, performing chronic peritoneal or home hemodialysis, with iron deficiency defined as ferritin < 100 ng/mL and/or an iron saturation < 20%.


METHODS
The total dose of iron dextran was calculated and infused at a rate not exceeding 6 mg/min. Hemoglobin, hematocrit, iron studies, and liver function tests (LFTs) were obtained before and 3 to 4 weeks after TDI infusion. Hematocrit of patients failing to achieve an increase in Hct over this period was re-examined 2 to 4 weeks later looking for a delayed response.


METHODS
Primary end points for efficacy were changes in Hct, ferritin, and iron saturation. Toxicity was measured as reported immediate and delayed symptoms and elevated transaminases and/or alkaline phosphatase levels.


RESULTS
A median iron dose of 1000 mg (range, 325-1500 mg) was administered. The infusions were generally well tolerated. Clinical adverse effects were seen in 2 patients weighing less than 50 kg. No increase in LFT results was seen. Hematocrit increased 2.2% (95% CI, 0.5%-3.9%) from 29.0% to 31.2% (p = 0.01) within 4 weeks of infusion. Significant increases also occurred in iron saturation (from 13% to 22%, p = 0.001) and ferritin (from 234 to 305 ng/mL, p = 0.008). Among the 9 patients who did not respond with a significant increase in Hct, 2 had a delayed response, increasing the overall response from 63% at 4 weeks to 71%, 8 weeks after TDI. Inadequate erythropoietin dosing and low-grade infectious/inflammatory disorders may have contributed to a poor response in several patients.


CONCLUSIONS
Total dose iron is a safe and effective means of restoring iron and erythropoietic response in ESRD patients weighing more than 50 kg who receive their renal replacement therapy at home.
Sloand
J A
JA
Department of Medicine, Highland Hospital, University of Rochester School of Medicine and Dentistry, New York 14620, USA.
Shelly
M A
MA
Erenstone
A L
AL
Schiff
M J
MJ
Talley
T E
TE
Dhakal
M P
MP
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006400:Hematocrit; D006437:Hemodialysis, Home; D006801:Humans; D007262:Infusions, Intravenous; D007505:Iron-Dextran Complex / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D011446:Prospective Studies
D006397:Hematinics; D007505:Iron-Dextran Complex